Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...

Stifel analysts adjusted their outlook on Atara Biotherapeutics (NASDAQ:ATRA) stock, reducing the price target to $5 from the previous $10, while maintaining a Hold rating on the shares. The decision ...

Wall Street analysts are buzzing with optimism as we step into 2025.  There are plenty of reasons for a positive view to ...

Stifel lowered the firm’s price target on Inspire Medical (INSP) to $190 from $200 and keeps a Hold rating on the shares. The firm notes in ...

Stifel analyst Drew Crum raised the firm’s price target on Take-Two (TTWO) to $223 from $220 and keeps a Buy rating on the shares. The firm ...

Altimmune Inc (ALT) stock saw a modest uptick, ending the day at $6.86 which represents a slight increase of $0.15 or 2.24% from the prior close of $6.71. The stock opened at $6.8 and touched a low of ...

The new president and congressional leaders are meeting Tuesday to hash out a strategy for maintaining US creditworthiness ...

TD Cowen has recently reiterated Nextdecade Corp (NEXT) stock to Buy rating, as announced on June 6, 2024, according to Finviz. Earlier, on August 16, 2023, Wolfe Research had raised the stock from a ...

David Swartz, a senior equity analyst at Morningstar Research Services, told Retail Dive that VF has been “cutting costs and ...

Vail Resorts issued its annual early season update to investors on Thursday, reporting that season-to-date total skier visits ...